Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)
Ryan B. Corcoran(Massachusetts General Hospital), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Elena Élez(Vall d'Hebron Hospital Universitari), Salvatore Siena(University of Milan), Gary Middleton(University Hospitals Birmingham NHS Foundation Trust), Rona Yaeger(Memorial Sloan Kettering Cancer Center), Y. Humblet(UCLouvain Saint-Louis Brussels), Takayuki Yoshino(University of Tsukuba), Chloé E. Atreya(The University of Texas MD Anderson Cancer Center), Michael S. Gordon(Pinnacle Oncology Hematology), Savina Jaeger, Kei Muro(Aichi Cancer Center), Thierry André(Inserm), Michel Ducreux(Université Paris-Saclay), Fatima Rangwala(Novartis (United States)), Autumn J. McRee(University of North Carolina at Chapel Hill), Matthew Squires(Novartis (United States)), Jan H.M. Schellens(Utrecht University), R. Sidhu(Amgen (United States)), Johanna C. Bendell(Dana-Farber Cancer Institute)
Cited by 46
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k